Biotech Values

[jbog]

RVNC’s CFO said on today’s CC that the company now has enough liquidity to fund operations until reaching profitability. I.e., no more share offerings and presumably no use of the ATM facility.

The company sates: "Revance expects its 2022 GAAP and non-GAAP operating expenses to be on the upper end of its previously announced guidance ranges of $375 million to $400 million and $260 million to $280 million, respectively. With current cash, cash equivalents and short-term investments of $378.6 million, an additional $100 million of notes available for issuance through Athyrium Capital, and anticipated revenues and expenditures, management projects that the company's U.S. aesthetics portfolio (DAXXIFY(TM), RHA(R) Collection, OPUL(R)) will be funded to cash flow breakeven."

The Flys interpretation and yours are not the same.

Very low probability if not downright silly.